The role of positron emission tomography imaging in movement disorders.

PET imaging provides the means to study neurochemical, hemodynamic, or metabolic processes that underlie movement disorders in vivo. Because the extent of presynaptic nigrostriatal dopaminergic denervation can be quantified in PD even at an early or preclinical stage of the disease, PET imaging may allow the selection of at-risk subjects for neuroprotective intervention trials. These techniques may also provide markers to follow progression of disease or evaluate the effects of neurorestorative interventions in patients who have more advanced disease. PET is expected to play an increasing role in the selection of patients who have PD for deep brain stimulation. Dopaminergic studies may have a limited clinical role in the diagnosis of patients who have symptoms that suggestive of PD yet do not respond to typical dopaminergic drugs, such as patients who have vascular parkinsonism or ET with mild resting tremor who may have normal dopaminergic innervation. The differential diagnosis between PD and multiple system atrophy, progressive supranuclear palsy, or corticobasal degeneration is not yet clearly established by PET, but combined pre- and postsynaptic dopaminergic imaging may be able to distinguish early idiopathic PD from atypical parkinsonian disorders, in general. Huntington's chorea is characterized by more prominent striatal dopamine receptor loss, whereas nigrostriatal denervation is present to a lesser degree. Patients who have TS may have enhanced synaptic dopamine release in the putamen. Functional imaging studies have generally failed to demonstrate nigrostriatal denervation in essential tremor or idiopathic dystonia. Studies have shown striatal dopamine receptor loss in selected subtypes of dystonic patients. In conclusion, it is expected that PET will help us to better understand the pathophysiology of movement disorders, increase the diagnostic accuracy, allow preclinical diagnosis, monitor disease progression, and evaluate the efficacy of therapeutic agents. Pharmacologic radioligand displacement studies and the development of new nondopaminergic ligands may further aid in the unraveling of cerebral mechanisms that underlie movement disorders.

[1]  A. Kishore,et al.  Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. , 1997, Journal of neural transmission. Supplementum.

[2]  B. Långström,et al.  Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET , 1996, Neurology.

[3]  S C Strother,et al.  Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  D. Eidelberg,et al.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M. Ernst,et al.  High presynaptic dopaminergic activity in children with Tourette's disorder. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  M. Hallett,et al.  Glucose metabolism in the brain of patients with essential tremor , 1993, Journal of the Neurological Sciences.

[7]  A. Kishore,et al.  Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography , 1998, Neurology.

[8]  S. Gilman,et al.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.

[9]  C. McDougle,et al.  [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. , 1995, The American journal of psychiatry.

[10]  D. Dickson,et al.  Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy , 2004, Acta Neuropathologica.

[11]  J R Moeller,et al.  Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. , 2001, Brain : a journal of neurology.

[12]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[13]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[14]  S. Augood,et al.  Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease , 1997, Annals of neurology.

[15]  G. Sawle,et al.  PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. , 1992, Advances in neurology.

[16]  R N Gunn,et al.  Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.

[17]  J R Moeller,et al.  The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[18]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[19]  A. E. Harding,et al.  Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.

[20]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[21]  S. Gilman,et al.  Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy , 1994, Annals of neurology.

[22]  S H Snyder,et al.  Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease , 1993, Annals of neurology.

[23]  S. Asenbaum,et al.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease , 2000, Journal of Neurology.

[24]  D Petersen,et al.  Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[25]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[26]  T Jones,et al.  Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease , 1985, Neurology.

[27]  D J Burn,et al.  Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study , 1997, Annals of neurology.

[28]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[29]  B. Bloem,et al.  [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[30]  Hirohide Takahashi,et al.  Positron emission tomographic studies of dopa‐responsive dystonia and early‐onset idiopathic parkinsonism , 1993, Annals of neurology.

[31]  J R Moeller,et al.  The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies , 1990, Movement disorders : official journal of the Movement Disorder Society.

[32]  A. Destée,et al.  Voxel‐based distribution of metabolic impairment in corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.

[33]  L. Deecke,et al.  [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.

[34]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[35]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .

[36]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[37]  D R Medoff,et al.  Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. , 1996, The American journal of psychiatry.

[38]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[39]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[40]  R. Coppola,et al.  Tourette Syndrome: Prediction of Phenotypic Variation in Monozygotic Twins by Caudate Nucleus D2 Receptor Binding , 1996, Science.

[41]  A. Lozano,et al.  Globus pallidus deep brain stimulation for generalized dystonia: Clinical and PET investigation , 1999, Neurology.

[42]  M. Hallett,et al.  Deficient activation of the motor cortical network in patients with writer’s cramp , 1999, Neurology.

[43]  C D Marsden,et al.  Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography , 1986, Movement disorders : official journal of the Movement Disorder Society.

[44]  Sid Gilman,et al.  Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography , 1988, Annals of neurology.

[45]  P. Lantos,et al.  The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. , 1994, Brain : a journal of neurology.

[46]  M. Sasaki,et al.  Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with18F-dopa and18F-FDG , 1997, Annals of nuclear medicine.

[47]  R. Albin,et al.  Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  P. Thompson,et al.  A positron emission tomography study of cerebral activation associated with essential and writing tremor. , 1995, Archives of neurology.

[49]  G Becker,et al.  Imaging the pre‐ and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: A SPECT STUDY Using [123I] epidepride and [123I] β‐CIT , 1998, Movement disorders : official journal of the Movement Disorder Society.

[50]  K. Bhatia,et al.  123I-IPT brain SPECT study in essential tremor and Parkinson’s disease , 1999, Neurology.

[51]  Richard S. J. Frackowiak,et al.  PET and movement disorders. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[52]  J. Missimer,et al.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. , 1995, Archives of neurology.

[53]  J. Perlmutter,et al.  Abnormal vibration-induced cerebral blood flow responses in idiopathic dystonia. , 1990, Brain : a journal of neurology.

[54]  Parkinson's disease and essential tremor , 1994, Neurology.

[55]  Yun Zhou,et al.  Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. , 2002, The American journal of psychiatry.

[56]  C. Marsden,et al.  Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia , 1995, Annals of neurology.

[57]  M. Raichle,et al.  Pure hemidystonia with basal ganglion abnormalities on positron emission tomography , 1984, Annals of neurology.

[58]  S J Kish,et al.  [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease , 1997, Neurology.

[59]  M. Trimble,et al.  Dopamine receptor availability in Tourette's syndrome , 1994, Psychiatry Research: Neuroimaging.

[60]  R. Albin,et al.  Decreased striatal monoaminergic terminals in Huntington disease , 2000, Neurology.

[61]  D. Kuhl,et al.  [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity , 1995, Neuroscience.

[62]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[63]  G. Firnau,et al.  [18F]Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine , 1978 .

[64]  A. Rajput,et al.  Significance of Parkinsonian Manifestations in Essential Tremor , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[65]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[66]  Richard S. J. Frackowiak,et al.  Preliminary report: activation of the cerebellum in essential tremor , 1990, The Lancet.

[67]  N. Quinn,et al.  Fortnightly Review: Parkinsonism—recognition and differential diagnosis , 1995, BMJ.

[68]  J. Jankovic,et al.  Decreased [18F]Spiperone Binding in Putamen in Idiopathic Focal Dystonia , 1997, The Journal of Neuroscience.

[69]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[70]  Peter Herscovitch,et al.  The Functional Neuroanatomy of Tourette's Syndrome: An FDG PET Study III: Functional Coupling of Regional Cerebral Metabolic Rates , 2002, Neuropsychopharmacology.

[71]  D. Brooks Imaging basal ganglia function , 2000, Journal of anatomy.

[72]  Richard S. J. Frackowiak,et al.  Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study , 1992, Annals of neurology.

[73]  P. Thompson,et al.  Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.

[74]  B Conrad,et al.  A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. , 1999, Archives of neurology.

[75]  Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[76]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[77]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[78]  A. Snyder,et al.  Diminished regional cerebral blood flow response to vibration in patients with blepharospasm , 1999, Neurology.

[79]  V. Dhawan,et al.  The metabolic anatomy of tremor in Parkinson's disease , 1998, Neurology.

[80]  S Lehéricy,et al.  Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography. , 1999, Archives of neurology.

[81]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[82]  V. Dhawan,et al.  Functional brain networks in DYT1 dystonia , 1998, Annals of neurology.

[83]  G. Sawle,et al.  PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[84]  K. Leenders,et al.  Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.

[85]  Y Agid,et al.  Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. , 1985, Brain : a journal of neurology.